Introduction
============

Baeyer-Villiger monooxygenases (BVMOs) are flavin-dependent enzymes capable of catalyzing the insertion of an oxygen atom between a C-C bond in carbonyl compounds (Baeyer-Villiger oxidation) such as ketones and aldehydes, yielding esters and lactones (Kamerbeek [@B16]). These enzymes can also oxidize C = C bonds to epoxides (Colonna [@B9]) and heteroatom-containing molecules; e.g. organic sulfides, amines and boron compounds (Brondani [@B5]). Therefore, BVMOs are able to work on either electron-poor or electron-rich molecules. Remarkably, different mechanisms have been proposed for these O~2~-driven reactions (Ottolina [@B25]). In the first case, a nucleophilic attack takes place resembling the chemical Baeyer-Villiger reaction conducted by peracids. Unlike this, to oxidize a heteroatom, an electrophilic attack might take place. A common feature among these mechanisms is the strict dependence of a reduced nicotinamide coenzyme (NAD(P)H) for the reduction of the flavin cofactor (FAD). In a subsequent step, the reduced flavin reacts rapidly with molecular oxygen to form a reactive peroxyflavin intermediate. Only after the oxygenation of the substrate, the enzyme reverts to the oxidized state. Subsequently the oxidized NAD(P)^+^ coenzyme is released. This latter process has been shown to be rate-determining in the kinetic mechanism studied for the BVMOs, cyclohexanone monooxygenase (CHMO) (Sheng [@B30]) and phenylacetone monooxygenase (PAMO) (Torres Pazmiño et al. [@B34][@B35]).

BVMOs are an attractive alternative in organic synthesis due to their relaxed substrate acceptance, their high chemo-, regio- and enantioselectivity, as well as their optimal activity in mild and environmentally-friendly conditions. Because of this, the last few years have witnessed a steady growth in research efforts towards discovery and engineering of BVMOs (Leisch [@B19]Balke [@B2]). By random mutagenesis and site directed evolution, it has been possible to expand the substrate specificity, as well as to improve and change the stereoselectivity of cyclopentanone monooxygenase (CPMO) (Clouthier and Kayser [@B8]) and CHMO (Zhang [@B41]), among others. Moreover, the designing of chimeric BVMOs by using the scaffold of the thermostable PAMO and introducing novel selectivities of other BVMOs has been developed. Interestingly, it has been demonstrated that the properties of chimeric BVMOs are not directly predictable from the parental enzyme features (van Beek [@B37]). Concerning the finding of novel BVMOs, the most striking, recently reported example is the large set of rhodococcal BVMOs that has been produced and characterized (Szolkowy [@B31]; Riebel [@B28]). The genome of *Rhodococcus jostii* was found to contain 22 type I BVMOs which were all functionally expressed and their biocatalytic properties assessed. This example has revealed that the sequence diversity among this class of flavoprotein monooxygenases is extremely broad, even within a single genome. Despite the recent efforts in discovery and engineering of novel enzymes, the number of recombinant available BVMOs is still rather modest and these are mainly derived from bacterial species.

Based on the exploration of sequenced genomes, it was proposed that fungal ones are rich in BVMO-encoding genes, especially within the *Aspergillus* genus (Torres and Fraaije [@B36]). In 2004, *A*. *parasiticus* aflatoxin gene cluster was completely sequenced revealing the presence of at least one putative BVMO encoding ORF (Yu [@B39]). The biosynthetic pathways for aflatoxins B~1~, G~1~ and B~2~, G~2~, starting from the early precursor nosrolinate anthrone, have been fully described (McGuire and Townsend [@B22]; Yu [@B40]). However, not all the involved enzymes have been identified at the molecular/biochemical level. Moreover, the genome of *A*. *parasiticus* has not been completely sequenced, therefore the presence of other BVMO genes can not be ruled out. More recently, the cythochalasin gene cluster from *A*. *clavatus* NRRL 1 has been identified and engineered. It was demonstrated that within the multi-domain polyketide synthase-nonribosomal peptide synthetase complex (PKS--NRPS), responsible for the cytochalasin E and K synthesis, there might be a BVMO (CcsB) which displays a rare reaction on a vinyl carbonate moiety (Qiao [@B26]). The sequencing of the *A*. *fumigatus* Af293 genome was reported in 2005 (Nierman [@B24]). This allergenic pathogen is known to be a source of toxic compounds such as helvolic acid and fumagillin, which are probably the result of biosynthetic routes that involve BVMOs. Moreover, an early step catalyzed by a PKS complex leading to a lactone moiety, was identified in the biosynthesis of the meroterpenoid pyripyropene (Itoh [@B14]). In addition to the genetic and molecular evidence of BVMOs occurrence, there are many biotransformation reports where *A*. *fumigatus* catalyzes Baeyer-Villiger oxidations and enantioselective sulfoxidations (Jones [@B15]Mascotti [@B21]). These biochemical evidences support the presence of more than one BVMO in this species. So far, only one fungal BVMO has been produced as a recombinant enzyme: cycloalkanone monooxygenase (CAMO) from the ascomycete *Cylindrocarpon radicicola* (Leipold et al. [@B18]). All other available recombinant BVMOs belong to prokaryotic genomes.

Herein we describe the identification of a set of BVMOs from *Aspergillus fumigatus* Af293. In particular, we have cloned, expressed and biochemically characterized BVMO~Af1~, being the first *Aspergillus*-derived BVMO to be reported.

Materials and methods
=====================

Chemicals
---------

All the reagents and chemicals were obtained from Across Organics and Sigma-Aldrich. Enzymes and oligonucleotides were purchased from Invitrogen, Sigma, NEB and Biodynamics. In-fusion™ 2.0 and Champion™ pET200 Directional TOPO® expression kits were purchased from Clonetech and Invitrogen, respectively.

Data mining and searching for *Aspergillus fumigatus* BVMOs
-----------------------------------------------------------

The NCBI server was used for protein and DNA sequence retrieval by using BLASTP and TBLASTN under default parameters (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>). By using PAMO and CHMO sequences (Bonsor [@B4]), *A*. *fumigatus* Af293 genomic, ESTs and protein databases were investigated for the presence of BVMO genes. The identified BVMO sequences were combined with the known bacterial BVMOs sequences and analyzed using CLUSTALW multiple alignment software (<http://www.ebi.ac.uk/Tools/msa/clustalw2/>). Further sequence analysis based on consensus motifs was made. Based on these sequence analyses, putative BVMO-encoding genes were identified.

Cloning and gene expression
---------------------------

Genomic DNA from *A*. *fumigatus* Af293 (obtained from the FGSC) was purified as described before (Dellaporta [@B10]). The three selected BVMO-encoding genes; *Af1* (XM_742067), *Af2* (XM_741856) and *Af3* (XM_750181) were amplified by PCR using a proofreading polymerase (Phusion DNA polymerase, NEB). Full length PCR products were cloned into the pET200/D TOPO vector. Based on the sequence alignment and domain analyses, a truncated form of *Af1* (1614 bp), full length *Af2* and a truncated form of *Af3* (1632 bp) were also cloned into a pCRE2 vector by using the In-Fusion PCR Cloning kit (Clontech) (see online resource for details). This vector harbors a codon-optimized gene encoding a mutant of phosphite dehydrogenase (PTDH) with an N-terminal His-tag (Torres Pazmiño [@B35]). For expression experiments, BL21(DE3) and TOP10 bacterial strains were transformed with pET200 and pCRE-based constructs, respectively. For expression optimization of pET200 constructs, cultures were grown at 37°C up to an OD~600~ of 0.5. IPTG was added at different final concentrations (1.0 and 0.5 mM) and cultures were grown for 6 h at four different temperatures (17, 24, 30 and 37°C). For TOP10 cells harboring pCRE2 constructs, expression was assessed using 24 deep square-well micro-titer plates with the sandwich cover system, shaking at 200 rpm. Cells were grown in the presence of different L-arabinose concentrations (0.002, 0.02, 0.2% *w*/*v*) at four different temperatures (17°C for 48 h, 24°C for 36 h, 30°C for 24 h and 37°C for 12 h). In both cases, cell extracts were obtained using DNase/lysozyme. Total extracts as well as clarified extracts were analyzed by SDS-PAGE upon blue staining (SimplyBlue™ SafeStain, Invitrogen) for detecting soluble expression of the enzyme.

Purification of recombinant BVMO~Af1~
-------------------------------------

The His-tagged PTDH-BVMO~Af1~ was purified using the following procedure: TOP10 cells harboring the pCRE-*Af1* construct, from 500 mL culture (36 h, 24°C, 0.02% *w*/*v* arabinose) were harvested by centrifugation. Cells were resuspended in 20 mL of 50 mM Tris/HCl pH 8.0 buffer containing 150 mM KCl, 10% (*v*/*v*) glycerol, 0.5 mM DTT, 0.5 mM PMSF and 100 μM FAD. Cells were disrupted by sonication and subsequently centrifuged (15,000 g for 45 min at 4°C, JA-17 rotor, Beckman Coulter). Clarified cell extract was loaded on 2 mL of Ni^2+^ Sepharose HP (GE Healthcare) and incubated for 1 h at 4°C while gently mixing. Then, the column was washed with three column volumes of 50 mM Tris/HCl pH 8.0, followed by three column volumes of same buffer containing 5.0 mM imidazole. The protein was eluted in the same buffer containing 500 mM imidazole. To remove imidazole, yellow fractions containing FAD-bound protein were applied on an Econo-Pac 10DG desalting column (Bio-Rad) pre-equilibrated with buffer Tris/HCl pH 8.0. The desalted and aliquoted protein was stored at -80°C.

The integrity and purity of protein samples were evaluated by SDS-PAGE. To quantify the purified enzyme, the extinction coefficient of FAD bound to PTDH-BVMO~Af1~ was determined as described previously (Fraaije [@B13]). UV--Vis absorption spectra were collected on a Perkin-Elmer Lambda Bio40 spectrophotometer.

Biocatalytic characterization
-----------------------------

Substrate screening was made according to the protocol described by Riebel ([@B28]). All substrates were tested at 2.5 mM. To analyze the enantioselectivity of PTDH-BVMO~Af1~, enzyme-mediated oxidations were performed using *rac*-bicyclo\[3.2.0\]hept-2-en-6-one and thioanisole as substrates. Reaction mixtures (1.0 mL) containing 50 mM Tris/HCl pH 8.0, 2.5 mM substrate, 50 μM NADPH, 10 mM phosphite and 1.0 μM enzyme were incubated for 4 h and/or 24 h at 25°C, 200 rpm. In the case of *rac*-bicyclo\[3.2.0\]hept-2-en-6-one, samples were taken at regular time-intervals. Reactions were quenched by addition of 1.0 mL ethyl acetate. The organic layer was dried over MgSO~4~ and subsequently analyzed by GC-FID as previously described (Kamerbeek [@B17]).

Enzyme activity
---------------

Enzyme activity was measured spectrophotometrically by monitoring the substrate-dependent decrease in NADPH at 340 nm (ϵ~340~ = 6.22 mM^-1^ cm^-1^). Reaction mixtures typically contained 50 mM Tris/HCl pH 8.0, 100 μM NADPH, 2.0 mM *rac*-bicyclo\[3.2.0\]hept-2-en-6-one and 0.05 to 0.35 μM of enzyme. All kinetic measurements were performed at 25°C using air-saturated buffers. To determine the coenzyme specificity, NAD(P)H concentrations ranging from 0.05 to 2.0 mM were tested. The observed rate constants were fitted with the Michaelis-Menten equation using SigmaPlot for Windows version 10.0.

Activity and thermal stability were measured spectrophotometrically by performing the reaction at different temperatures, ranging from 20 to 55°C. The melting point was determined by the previously described method Thermo-FAD (Forneris [@B11]). Activity and stability over pH were measured by performing the reaction at different pHs. The Britton & Robinson buffer (Thomas [@B33]Baldrian [@B1]) at a concentration of 50 mM was used in the pH range of 4.0-10.0.

The activity in the presence of 5% (*v*/*v*) of ethanol, methanol, *t*-butanol, dioxane and DMSO was tested. To check the enzyme stability, enzyme was pre-incubated for 1 h at room temperature in the presence of 5% (*v*/*v*) of the selected solvents, and remaining activity was measured spectrophotometrically. The same protocol was followed to test activity in other conditions such as the presence of salts, glycerol and different buffer types.

Results
=======

Mining the *A. fumigatus* Af293 genome for BVMO-encoding genes
--------------------------------------------------------------

By using the sequences of previously reported BVMOs (PAMO & CHMO) as probes, 13 predicted proteins from *A*. *fumigatus* with significant similarity (E-value \< 1.10^-6^) were retrieved by BLASTP. No additional sequences were retrieved by TBLASTN on genomic and mRNA databases. The retrieved protein sequences were curated by confirming the presence of BVMO-typifying sequence hallmarks, namely two Rossmann folds GxGxx(G/A) flanking the FxGxxxHxxxW(P/D) motif (Fraaije [@B12]). Single amino acid substitutions were allowed in the latter motif (F/Y or H/Q). Nine predicted genes/proteins fulfilling these requirements were selected as putative BVMOs, XM_742067 (protein id XP_747160), XM_741856 (protein id XP_746949), XM_750181 (protein id XP_755274), XM_750991 (protein id XP_75684), XM_749026 (protein id XP_754119), XM_746162 (protein id XP_751255), XM_742681 (protein id XP_747774), XM_747111 (protein id XP_75224), XM_746209 (protein id XP_75132). These nine ORFs were aligned to genomic sequences to detect the presence of introns. Based on this, the three intronless nucleotide sequences XM_742067 (protein id XP_747160), XM_741856 (protein id XP_746949) and XM_750181 (protein id XP_755274) named *Af1*, *Af2* and *Af3* respectively, were chosen to be cloned and expressed (Figure [1](#F1){ref-type="fig"}). The enzymes encoded by the selected genes were named BVMO~Af1~, BVMO~Af2~, and BVMO~Af3~, according to their source strain, *A*. *fumigatus*.

![**Multiple sequence alignment of some BVMOs sequences.** Sequences are: BVMO~Af1~ (XP_747160), BVMO~Af2~ (XP_746949) and BVMO~Af3~ (XP_755274) from *A*. *fumigatus* Af293, PAMO (YP_289549) from *Thermobifida fusca*, CHMO (AAG10021) from *Acinetobacter* sp., HAPMO (AAK54073) from *Pseudomonas fluorescens*, CPDMO (BAE93346) from *Pseudomonas* sp. HI70 and CAMO (AET80001.1) from *Cylindrocarpon radicicola*. The two Rossmann folds (GxGxxG) and the BVMO fingerprint (FxGxxxHxxxWP/D) are highlighted.](2191-0855-3-33-1){#F1}

The predicted BVMO~Af1~ contains 905 amino acids comprising an N-terminal BVMO domain (\~540 residues) fused to a \~360 amino acids long putative polynucleotide synthase domain. For this reason, a truncated version of BVMO~Af1~ (1614 bp) was obtained by deleting 367 C-terminal residues. The two Rossmann fold motifs are conserved and confirm that the protein binds FAD and NADPH. Besides, in the BVMO fingerprint motif the conserved His residue is replaced by Gln.

BVMO~Af2~ is predicted to be a single, 486 amino acids-long, BVMO-domain. The full length encoding gene (1461 bp) was cloned in expression vectors. The BVMO fingerprint as well as the two Rossmann fold motifs are fully conserved in this protein.

The BVMO~Af3~ amino acid sequence presents an N-terminal extension of 58 residues compared to other BVMOs. In this case, a truncated fragment of 1632 bp was subcloned, in which the N-terminal extension was removed in order to prevent incorrect folding of the recombinant protein. This truncated enzyme comprised 543 amino acids and has canonical BVMO fingerprint and Rossmann fold motifs.

Cloning and expression of recombinant *A. fumigatus* BVMOs
----------------------------------------------------------

Two approaches were assessed. First, the three selected full-length sequences were cloned as 6×His fusion into a pET vector under the control of a T7 promoter. Small-scale expression conditions were tested for all these constructs. The pET-*Af1* and pET-*Af3* constructs yielded no soluble protein expression, as detected by SDS-PAGE. The pET-*Af2* construct allowed us to obtain soluble protein, although at a low expression level. In addition, the expressed BVMO~Af2~ did not show affinity towards the Ni^2+^ resin, preventing affinity chromatography purification. However, activity assays using crude extracts of *E*. *coli* cells expressing BVMO~Af2~ revealed that this enzyme is active (data not shown). In the case of the *Af1* gene, we hypothesize that the large C-terminal domain could be responsible for protein aggregation. Therefore, we tested the expression and solubility of the cloned BVMOs domains fused to an N-terminal His-tagged, cofactor regenerating protein; PTDH. Expression tests of these constructs revealed no detectable expression of BVMO~Af2~ or BVMO~Af3~, whereas BVMO~Af1~ yielded high expression of a soluble protein of the expected molecular weight. This result proves that fusion proteins may have a beneficial influence in the expression of non-soluble proteins, such it was the case of BVMO~Af1~, a fact that has been also reported for other BVMOs (Thapa [@B32]). Therefore, larger scale expression and purification were performed for this PTDH-BVMO fusion protein.

In the case of pCRE2-*Af2* construct the lack of expression may be due to the deletion of the N-terminal tail. For the gene *Af3*, functional expression was not achieved in any of the tested conditions indicating that a different expression system may be suitable in this case.

Purification and spectral characterization of PTDH-BVMO~Af1~
------------------------------------------------------------

From a 2 L culture, 33 mg of His-tagged protein could be purified. The protein migrated as a single band on SDS-PAGE, corresponding to a mass of 100 kDa. This is in good agreement with the calculated mass for the PTDH-BVMO~Af1~ fusion protein (35 + 60.5 kDa). The yellow purified protein displayed two absorption maxima at 380 nm and 449 nm, as it is expected for a flavoprotein. The estimated extinction coefficient for the purified enzyme was determined as ϵ~449~ = 13.3 mM^-1^ cm^-1^. The addition of NADPH resulted in a complete reduction of the flavin evidenced by the spectral analysis, strongly suggesting that the recombinant protein is functional (Figure [2](#F2){ref-type="fig"}). The ratio of A~280~/A~449~ was found to be 14, indicating that the protein is mainly in its holo form.

![**Spectral characterization of BVMO**~**Af1**~**.** Visible spectra of native BVMO~Af1~ (solid line) and BVMO~Af1~ after unfolding by 1% SDS and incubation at 80°C (dotted line). Spectral changes observed upon reduction of BVMO~Af1~ by excess of NADPH (dashed line).](2191-0855-3-33-2){#F2}

Catalytic properties
--------------------

In order to evaluate the biocatalytic potential of the recombinant enzyme, a set of 46 possible substrates was tested, including linear, cyclic, bicyclic and aromatic ketones, steroids, aromatic prochiral sulfides, diketones and bifunctional molecules. The assay revealed that four compounds namely *rac*-bicyclo\[3.2.0\]hept-2-en-6-one, benzyl ethyl sulfide, thioanisole and 3-phenylpentane-2,5-dione triggered significant NADPH consumption, which was evidenced by the phosphate production (Additional file [1](#S1){ref-type="supplementary-material"}: Table S2). In order to confirm the enzyme BVMO activity and to assess its enantioselectivity, reactions were carried out using the model substrate *rac*-bicyclo\[3.2.0\]hept-2-en-6-one since both enantioselectivity and regioselectivity, can be simultaneously tested (Mihovilovic [@B23]). In this reaction a kinetic resolution process takes place, the migration of the more-substituted carbon atom generates the "normal" lactone, while the migration of the less-substituted carbon atom forms the "abnormal" lactone (Renz and Meunier [@B27]). It was observed that BVMO~Af1~ converted the substrate in a highly selective fashion, successfully achieving the kinetic resolution of the substrate. The normal lactone (1*S*,5*R*)-2-oxabicyclo\[3.3.0\]oct-6-en-3-one (*ee* \> 99%) was generated in a fast reaction, and full conversion was reached after 45 min. In contrast, the abnormal lactone (1*R*,5*S*)-3-oxabicyclo\[3.3.0\]oct-6-en-2-one (*ee* \> 99%) was the product of a slow reaction and full conversion was achieved at 4 h (Figure [3](#F3){ref-type="fig"}). The ratio of the regioisomeric products was 1:1, with excellent optical purities of the formed lactones.

![**Oxidation of*rac*-bicyclo\[3.2.0\]hept-2-en-6-one catalyzed by BVMO**~**Af1**~**.** (**A**) Time course BVMO~Af1~-catalyzed oxidation of *rac*-bicyclo\[3.2.0\]hept-2-en-6-one (1) to 2-oxabicyclo\[3.3.0\]oct-6-en-3-one (2) and 3-oxabicyclo\[3.3.0\]oct-6-en-2-one (3). (**B**) Structural formulas of bicyclo \[3.2.0\]hept-2-en-6-one isomers and lactones formed by BVMO~Af1~ activity.](2191-0855-3-33-3){#F3}

When thioanisole was tested as prochiral substrate, 88% conversion was achieved after 2 h. The (*S*)-sulfoxide was obtained with excellent enantioselectivity (*ee* \> 99%). A similar optical purity was observed when the substrate was benzyl ethyl sulfide (Table [1](#T1){ref-type="table"}). In both cases, sulfone formation was detected. In case of thioanisole, a small amount was produced after 2 h of conversion. On the other hand, in the case of benzyl ethyl sulfide the amount of sulfone was higher at shorter reaction times.

###### 

**Sulfides conversion catalyzed by BVMOAf1**~**Af1**~

         **Substrate**          **Time** (**min**)^**a**^   **Sulfoxide** (%)   **Sulfone** (%)   **ee** (%)
  ---------------------------- --------------------------- ------------------- ----------------- ------------
   ![](2191-0855-3-33-i1.gif)              180                     88                  8          \>99 (*S*)
   ![](2191-0855-3-33-i2.gif)              60                      56                 37          \>99 (*S*)
              180                          25                      75             \>99 (*S*)     

^a^ Reactions were monitored by sampling at regular time intervals. Full substrate conversion was observed at 180 min in both cases. For GC conditions, see online resource.

Steady-state kinetic measurements
---------------------------------

Steady-state kinetic parameters were determined for three of the substrates (Table [2](#T2){ref-type="table"}). NADPH was found to be very well recognized by BVMO~Af1~ (K~*M*~ value \< 5 μM). No significant activity was detected with NADH concentrations up to 1.0 mM, showing that this enzyme only accepts NADPH as hydride donor. BVMO~Af1~ highest apparent affinity was towards benzyl ethyl sulfide (K~*M*~ = 23.5 μM). The maximal rate of catalysis was in the same range for all the tested substrates, *k*~*cat*~ ≈ 0.5 s^-1^. This suggests that the conversion rates are independent of the type of substrate and hints to a rate-limiting step that does not involve the oxygenation reaction. Further kinetics analyses will reveal the rate limiting step during catalytic cycle.

###### 

**Steady**-**state kinetic parameters of BVMO**~**Af1**~

        ***Substrate***         ***K***~***M***~**(μ*M*)**   ***k***~***cat***~**(*s***^**-**\ ***1***^**)**   ***k***~***cat***~**/*K***~***M***~**(*s***^**-**\ ***1***^**/*mM***^**-**\ ***1***^**)**
  ---------------------------- ---------------------------- ------------------------------------------------- -------------------------------------------------------------------------------------------
   ![](2191-0855-3-33-i3.gif)           23.5 ± 0.1                             0.47 ± 0.04                                                                20
   ![](2191-0855-3-33-i4.gif)          118.8 ± 0.1                             0.46 ± 0.02                                                                4.1
   ![](2191-0855-3-33-i5.gif)          179.8 ± 0.1                             0.36 ± 0.06                                                                2.0

Optimal conditions for activity & stability
-------------------------------------------

Optimal temperature was determined toward *rac*-bicyclo\[3.2.0\]hept-2-en-6-one. It was found that the enzyme exhibits its highest activity at 50°C (Figure [4](#F4){ref-type="fig"}-A). Based on this observation, the remaining activity was measured after 1.5 h of pre-incubation at different temperatures (20, 30, 35, 40, 50 and 60°C) and no significant loss of activity was detected up to 35°C (Figure [4](#F4){ref-type="fig"}-B). The melting temperature (T~m~) was 41.1°C and 43.3°C in Tris/HCl and phosphate buffers, respectively. The difference between both values could be attributed to the ionic nature of phosphate buffer, which may change the unfolding temperature, as it has been previously described for other enzymes (Cacace [@B6]). Alternatively, the inorganic phosphate may occupy binding pockets that are normally occupied by the phosphate moieties of NADP^+^ during catalysis, thereby stabilizing the enzyme.

![**Optimal conditions for activity.** (**A**) temperature-dependent activity profile, (**B**) temperature-dependent stability, for which the remaining activity was measured after 1.5 h incubation at the indicated temperatures, (**C**) pH-dependent activity profile, and (**D**) pH-dependent stability profile, by measuring the activity after 1 h incubation at different pH values. The error bars indicate standard deviations.](2191-0855-3-33-4){#F4}

The optimum pH for activity was determined to be 8.0, a typical value for Type I BVMOs (Figure [4](#F4){ref-type="fig"}-C). The effect of protein pre-incubation during 1 h at different pH values was also evaluated. Notably, the enzyme remained active at pHs ranged from 6.0 to 10.0 (Figure [4](#F4){ref-type="fig"}-D). Different buffers were tested but no significant changes were observed among them.

The addition of organic solvents to enzyme-catalyzed procedures is usually used to improve the solubility of the substrate/product and/or to increase the reaction yield. Therefore, the activity of BVMO~Af1~ in the presence of ethanol, methanol, *t*-butanol, dioxane and DMSO (5% *v*/*v*) was evaluated. None of the solvents significantly influenced the enzyme activity. Based on this, enzyme stability towards these solvents was tested. Remarkably, the enzyme remained fully active after 1 h of pre-incubation with all the solvents, showing a very good tolerance to harsh reaction conditions (Figure [5](#F5){ref-type="fig"}).

![**BVMO**~**Af1**~**stability in organic solvents.** Activity was measured after 1.0 h incubation in the presence of 5% (*v*/*v*) of organic solvents at room temperature. As control, no solvent was added to the buffer. The error bars indicate standard deviations.](2191-0855-3-33-5){#F5}

Discussion
==========

In this study we have identified nine nucleotide sequences in the genome of *A*. *fumigatus* Af293 that contain all sequence hallmarks that, at the protein sequence level, are typical for Type I BVMOs. Interestingly, sequence identity among these predicted enzymes is rather low (ranging from 15% to 40%). Therefore, this fungus is a very interesting model to understand the genetic and molecular basis of the diversity of these enzymes within eukaryotic genomes, such as *Rhodococcus* is a model for prokaryotes (Balke [@B2]). Besides, from a biocatalytic point of view, this fact could explain the whole-cell activity of *A*. *fumigatus* toward a broad range of substrates (Bastos Borges [@B3]). Moreover, the poor stereoselectivity evidenced in some cases could be explained to the occurrence of different BVMOs with opposite selectivities (Mascotti [@B21]). To explore the biocatalytic potential of these fungal BVMOs, we have cloned three of these genes and succeeded in the effective expression of one of the targeted BVMOs, BVMO~Af1~. A thoroughly characterization of this first recombinant *Aspergillus* BVMO has been performed.

The BVMO~Af1~ primary sequence shows 37% identity with the only eukaryotic BVMO previously described, CAMO (Leipold [@B18]). It displays a higher degree of homology with bacterial BVMOs (40% for CHMO from *Acinetobacter* and 42% for PAMO from *Thermobifida fusca*). Interestingly, BVMO~Af1~ has an amino acid substitution (H173Q) in the consensus BVMO motif. This residue has been proposed to be involved in conformational changes during the catalytic cycle, acting as a linker between the FAD and NADPH binding sites (Malito [@B20]). The mutation of the central His residue in other BVMOs has dramatic effects, such as reduced catalytic efficiency in the case of CHMO (Cheesman [@B7]) or inactivation in the case of HAPMO (Fraaije [@B12]). However, wild type BVMO~Af1~ proved to be active and highly stereoselective. The observed mild mutation is also in line with the finding that some rhodococcal BVMOs do not have a fully conserved BVMO motif ( Riebel [@B28]).

Intriguingly, there are no shared structural features among the identified substrates for this new enzyme. Therefore, we have named it BVMO~Af1~, according to its source organism. The low number of identified substrates for BVMO~Af1~ can be related to the fact that the activity screening assay has been designed based on the reported substrates for prokaryotic BVMOs. Nevertheless, the observed enantioselectivity was excellent in the bicyclic ketone oxidation as well as in the oxidation of thioanisole and benzyl ethyl sulfide. As control, conversion of cyclohexanone and phenylacetone were evaluated. Although these two ketones are accepted by many of the known BVMOs, no conversion was detected with BVMO~Af1~ and the substrates were fully recovered. These results showed that the enzyme is highly chemo-, regio-, and stereoselective, proving its interesting biocatalytic potential. The exploration of different substrates is currently underway in our laboratory.

From the steady state kinetic analysis of BVMO~Af1~, it was found that the *k*~*cat*~ values are rather modest (0.5 s^-1^) and independent of the type of substrate. This fact led us to propose that a predetermined reaction rate is expected for any compound capable of entering into the active site and react with the peroxyflavin. This assumption suggests that a kinetic event before or after oxygenation is limiting the rate of catalysis. To determine if the catalytic mechanism of this eukaryotic protein resembles that of the well-studied bacterial BVMOs, more detailed kinetic studies are necessary. Also, a very strict dependence of NADPH as cofactor was determined. This is a typical feature of all reported BVMOs so far, except for MekA from *Pseudomonas veronii* which seems to accept either NADH or NADPH as hydride donors ( Völker et al. [@B38]).

By testing different parameters such as temperature, pH and the addition of organic solvents, it was demonstrated that BVMO~Af1~ is a robust biocatalyst. Remarkably, the pre-incubation of the enzyme either in a broad pH range or in organic solvents resulted in no loss of activity. For some other enzymes it has been shown that the presence of organic solvents in the reaction media, even without longer incubation times, dramatically reduces the activity. For instance, the prototype BVMO, cyclohexanone monooxygenase, loses dramatically its activity when it is incubated with 5% of solvents and its tolerance is very poor, since after 20 min incubation with 5% methanol the enzyme is completely inactivated ( Secundo [@B29]). These features, in combination with the biocatalytic properties of BVMO~Af1~, make this enzyme a promising biocatalyst.

BVMO~Af1~ has been extensively studied in this work, proving that this fungal enzyme has typical BVMO characteristics. However, there are some special features such as the substrate scope, the kinetic parameters and its high tolerance to harsh conditions that open new questions about eukaryotic BVMOs and encourage the work with other fungal enzymes belonging to this class.
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